Talk about TD

May 5-11, 2024, Is Tardive Dyskinesia (TD) Awareness Week

This Mental Health Awareness Month, we are proud to recognize May 5-11, 2024, as Tardive Dyskinesia (TD) Awareness Week to help increase awareness and support people living with this burdensome condition.

TD is a persistent, involuntary movement disorder that is characterized by uncontrollable, abnormal and repetitive movements of the face, torso, limbs and fingers or toes.1-4 The condition is associated with prolonged use of antipsychotic medication that may be necessary to treat individuals living with mental illness, such as bipolar disorder, depression, schizophrenia and schizoaffective disorder.3,5,*

There are approximately 600,000 people in the United States living with TD, and approximately 65 percent have not yet been diagnosed.2,8,9

By declaring the first full week of May as TD Awareness Week, we are helping to raise awareness regarding: 

  • The signs and symptoms associated with TD 
  • The potential physical, social and emotional consequences of TD10 
  • The importance of speaking with a healthcare provider about the impact of the uncontrollable movements and available treatment options 

The uncontrollable movements of TD can negatively impact people physically, socially and emotionally.10 It can affect one’s ability to work, drive, walk, button a shirt or eat and drink.8 People living with TD may also feel judged and ashamed, adding to a sense of worry, isolation and stigma.1,10,13-15

Thank you for your commitment to raising awareness of TD and supporting the mental health community. We encourage everyone across Florida to acknowledge the first full week of May as TD Awareness Week. To learn more about TD, visit

*Certain prescription medicines (metoclopramide and prochlorperazine) used to treat gastrointestinal disorders may also cause TD.6,7


Task Force on Tardive Dyskinesia. Tardive dyskinesia: a task force report of the American Psychiatric Association. 1992. 2. Cloud LJ, Zutshi D, Factor SA. Tardive dyskinesia: therapeutic options for an increasingly common disorder. Neurotherapeutics. 2014;11(1):166- 176. doi:10.1007/s13311-013-0222-5 3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders.

5th ed., text revision. American Psychiatric Association; 2023. 4. Guy W. ECDEU Assessment Manual for Psychopharmacology. National Institute of Mental Health; 1976. 5. Caroff SN, Hurford I, Lybrand J, Campbell EC. Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial. Neurol Clin. 2011;29(1):127-148, viii. doi:10.1016/j.ncl.2010.10.002 6. Kenney C, Hunter C, Davidson A, Jankovic J. Metaclopramide, an increasingly recognized cause of tardive dyskinesia. J Clin Pharmacol. 2008;48(3):379- 384. doi:10.1177/0091270007312258 7. Sanger GJ, Andrews PLR. A history of drug discovery for treatment of nausea and vomiting and the implications for future research. Front. Pharmacol. 2018;9:913. doi:10.3389/fphar.2018.00913 8. Data on file. Neurocrine Biosciences, Inc. 9. Carbon M, Hsieh CH, Kane JM, Correll CU. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J Clin Psychiatry. 2017;78(3):e264–e278. doi: 10.4088/JCP.16r10832 10. Ascher-Svanum H, Zhu B, Faries D, Peng X, Kinon BJ, Tohen M. Tardive dyskinesia and the 3-year course of schizophrenia: results from a large, prospective, naturalistic study. J Clin Psychiatry. 2008;69(10):1580-1588. doi:10.4088/jcp.v69n1008 11. National Alliance for Mental Illness.

Mental health by the numbers. Accessed January 27, 2021.

Reinert M, Fritze D, Nguyen T. The state of mental health in America 2023. Mental Health America; 2022. 13. Boumans CE, de Mooij KJ, Koch PA, van ‘t Hof MA, Zitman FG. Is the social acceptability of psychiatric patients decreased by orofacial dyskinesia? Schizophr Bull. 1994;20(2):339-344. doi:10.1093/schbul/20.2.339 14. Yassa R. Functional impairment in tardive dyskinesia: medical and psychosocial dimensions. Acta Psychiatr Scand. 1989;80(1):64-67. doi:10.1111/j.1600-0447.1989.tb01301.x. 15. Citrome L. Clinical management of tardive dyskinesia: five steps to success. J Neurol Sci. 2017;383:199-204. doi:10.1016/j.jns.2017.11.019


More Posts

Stay Connected

Sign up to receive emails about upcoming NAMI events, programs and services in Collier County.

Full Name(Required)